Clinical trial management system

Cardiac Dimensions Appoints Angie Swenson as Vice President, Clinical Operations

Retrieved on: 
Thursday, January 26, 2023
Medical Devices, Health, Surgery, Clinical Trials, General Health, Cardiology, Valve, St. Jude Medical, Health technology, Hennepin County Medical Center, HLT, Area studies, Regulation, STEMI, Patient, Minnesota State University, Mankato, Clinical trial, TAVR, Dimension, Clinical trial management system, University, Beckman Coulter, Hypothermia, Trial of the century, Associate, Clinical research, Tricuspid valve, FDA, Bard (company), Heart failure, Cardiovascular disease, Angioplasty, Medical device

Cardiac Dimensions ®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the appointment of Angie Swenson as Vice President of Clinical Operations.

Key Points: 
  • Cardiac Dimensions ®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the appointment of Angie Swenson as Vice President of Clinical Operations.
  • Ms. Swenson has spent most of the last 20 years leading clinical trials in the U.S., Europe, Japan and Canada and collaborating on reimbursement strategies for therapies targeting cardiovascular disease developed by leading medtech innovators.
  • Most recently, she served as Vice President, Clinical and Regulatory for HLT, Inc., developer of transcatheter aortic heart valve replacement (TAVR) technology, where for five years she led their early feasibility studies.
  • Earlier in her career, she worked for Beckman Coulter as a Clinical Studies Scientist validating projects for FDA submissions.

Successful Approaches from Rare Disease and Cellular and Gene Therapy Product Approvals, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, February 13, 2023
Gene editing, MB, Doctor of Philosophy, Regulatory affairs, Common, EMA, Clinical trial, Clinical trial management system, Rare disease, European Medicines Agency, FDA, Bachelor of Science, US Foods, Rare, MD, Pharmaceutical industry, Medpace

TORONTO, Feb. 13, 2023 /PRNewswire-PRWeb/ -- Clinical development is becoming increasingly complex with continuing innovations in cell and gene therapies, especially when factoring in the hurdles of rare disease research. To achieve cell and gene therapy approvals in rare diseases, it is essential to overcome challenges specific to these trials.

Key Points: 
  • In this free webinar, gain insights into successful approaches for achieving cell and gene therapy approvals in rare diseases.
  • The featured speakers will share lessons learned in planning and conducting advanced therapy clinical trials in rare diseases.
  • To achieve cell and gene therapy approvals in rare diseases, it is essential to overcome challenges specific to these trials.
  • Register now for the webinar on Rare Disease Day 2023 to join the discussion with Medpace medical, regulatory and operational experts on successful approaches for achieving cell and gene therapy approvals in rare diseases.

BSI LIFE SCIENCES AND LEDGER RUN PARTNER TO STREAMLINE CLINICAL BUSINESS OPERATIONS

Retrieved on: 
Wednesday, February 8, 2023
Clinical data management, BSI, Patient, Clinical trial, CTMS, Clinical trial management system, Partnership, Fine chemical

BADEN, Switzerland and TIBURON, Calif., Feb. 8, 2023 /PRNewswire/ -- BSI Life Sciences specializes in state-of-the-art software for life sciences (CTMS, eTMF and more) and Ledger Run, Inc., an innovative technology company focused on optimizing clinical operations in the areas of site budgeting and payments, announced their partnership today. Through the partnership, BSI Life Sciences' Clinical Trial Management software BSI CTMS™  and Ledger Run's unique ClinRun™ platform will streamline and enhance clinical operation budgeting and payment processes with an intelligent approach and seamless integration.

Key Points: 
  • BADEN, Switzerland and TIBURON, Calif., Feb. 8, 2023 /PRNewswire/ -- BSI Life Sciences specializes in state-of-the-art software for life sciences (CTMS, eTMF and more) and Ledger Run, Inc. , an innovative technology company focused on optimizing clinical operations in the areas of site budgeting and payments, announced their partnership today.
  • Through the partnership, BSI Life Sciences' Clinical Trial Management software BSI CTMS™  and Ledger Run's unique ClinRun™ platform will streamline and enhance clinical operation budgeting and payment processes with an intelligent approach and seamless integration.
  • We help our customers to continuously optimize the clinical development processes in providing easy-to-use and easy-to-integrate CTMS and eTMF systems" said Jan Nielsen, Community Manager Life Sciences at BSI.
  • "Partnering with Ledger Run will further enhance our ability to tailor our digital solutions to enable our customers to optimize their clinical operations including payments.

BSI LIFE SCIENCES AND LEDGER RUN PARTNER TO STREAMLINE CLINICAL BUSINESS OPERATIONS

Retrieved on: 
Wednesday, February 8, 2023
Clinical data management, BSI, Patient, Clinical trial, CTMS, Clinical trial management system, Partnership, Fine chemical

BADEN, Switzerland and TIBURON, Calif., Feb. 8, 2023 /PRNewswire/ -- BSI Life Sciences specializes in state-of-the-art software for life sciences (CTMS, eTMF and more) and Ledger Run, Inc., an innovative technology company focused on optimizing clinical operations in the areas of site budgeting and payments, announced their partnership today. Through the partnership, BSI Life Sciences' Clinical Trial Management software BSI CTMS™  and Ledger Run's unique ClinRun™ platform will streamline and enhance clinical operation budgeting and payment processes with an intelligent approach and seamless integration.

Key Points: 
  • BADEN, Switzerland and TIBURON, Calif., Feb. 8, 2023 /PRNewswire/ -- BSI Life Sciences specializes in state-of-the-art software for life sciences (CTMS, eTMF and more) and Ledger Run, Inc. , an innovative technology company focused on optimizing clinical operations in the areas of site budgeting and payments, announced their partnership today.
  • Through the partnership, BSI Life Sciences' Clinical Trial Management software BSI CTMS™  and Ledger Run's unique ClinRun™ platform will streamline and enhance clinical operation budgeting and payment processes with an intelligent approach and seamless integration.
  • We help our customers to continuously optimize the clinical development processes in providing easy-to-use and easy-to-integrate CTMS and eTMF systems" said Jan Nielsen, Community Manager Life Sciences at BSI.
  • "Partnering with Ledger Run will further enhance our ability to tailor our digital solutions to enable our customers to optimize their clinical operations including payments.

Clinical Trials Management System Market Worth $4.72 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Monday, January 16, 2023
Cloud, International Federation of Pharmaceutical Manufacturers & Associations, Patient safety, CTMS, Clinical trial, ML, Medication, COVID-19, Cros, Clinical trial management system, Biotechnology, IQVIA, Machine learning, Research, Conditional sentence, Neurology, Vaccine, AI, Calendar, Drug development, Infection, Software, EDC, Prevalence, Component, Oracle, Cancer, Revenue, SAN, EHR, USD, Investment, Pharmaceutical industry, Medical device, Generic drug

The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, number of decentralized trials, and product enhancements.

Key Points: 
  • The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, number of decentralized trials, and product enhancements.
  • Key Industry Insights & Findings from the report:
    The Clinical Trials Management System (CTMS) market was valued at USD 1.66 billion in 2022 and is expected to expand at a CAGR of 14.3% during the forecast period.
  • Clinical Trial Management System is one of the three applications of IQVIA's Digital Trial Management Suite.
  • Grand View Research has segmented the clinical trials management system market based on solution type, delivery mode, component, end-user, and region
    Clinical Trials Management System (CTMS) Market - Solution Type Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - Delivery Mode Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - Component Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - End-user Outlook (Revenue, USD Million, 2017 - 2030)

Clinical Trials Management System Market Worth $4.72 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Monday, January 16, 2023
Cloud, International Federation of Pharmaceutical Manufacturers & Associations, Patient safety, CTMS, Clinical trial, ML, Medication, COVID-19, Cros, Clinical trial management system, Biotechnology, IQVIA, Machine learning, Research, Conditional sentence, Neurology, Vaccine, AI, Calendar, Drug development, Infection, Software, EDC, Prevalence, Component, Oracle, Cancer, Revenue, SAN, EHR, USD, Investment, Pharmaceutical industry, Medical device, Generic drug

The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, number of decentralized trials, and product enhancements.

Key Points: 
  • The key factors driving the market growth include the rising number of clinical trials, digitalization across healthcare R&D, number of decentralized trials, and product enhancements.
  • Key Industry Insights & Findings from the report:
    The Clinical Trials Management System (CTMS) market was valued at USD 1.66 billion in 2022 and is expected to expand at a CAGR of 14.3% during the forecast period.
  • Clinical Trial Management System is one of the three applications of IQVIA's Digital Trial Management Suite.
  • Grand View Research has segmented the clinical trials management system market based on solution type, delivery mode, component, end-user, and region
    Clinical Trials Management System (CTMS) Market - Solution Type Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - Delivery Mode Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - Component Outlook (Revenue, USD Million, 2017 - 2030)
    Clinical Trials Management System (CTMS) Market - End-user Outlook (Revenue, USD Million, 2017 - 2030)

RealTime Software Solutions Acquires Complion

Retrieved on: 
Wednesday, December 7, 2022
Factor X, Clinical data management, NIH, Acquisition, Clinical trial management system, Edoc, Partnership, Research, Hospital, CTMS, Cros, Academic health science centre, ESourcing Capability Model, Epiregulin, MD–PhD, AMCS, SAN, TEXT, Pharmaceutical industry, Online shopping, Text

SAN ANTONIO, Dec. 7, 2022 /PRNewswire/ -- RealTime Software Solutions, LLC, a leader in cloud-based software solutions for the clinical research industry, is pleased to announce the acquisition of Complion, Inc., a leading electronic regulatory (eReg)/electronic Investigator Site Files (eISF) solution provider for clinical research sites, academic medical centers (AMCs), hospitals, health systems, sponsors and contract research organizations (CROs).

Key Points: 
  • SAN ANTONIO, Dec. 7, 2022 /PRNewswire/ -- RealTime Software Solutions, LLC, a leader in cloud-based software solutions for the clinical research industry, is pleased to announce the acquisition of Complion, Inc., a leading electronic regulatory (eReg)/electronic Investigator Site Files (eISF) solution provider for clinical research sites, academic medical centers (AMCs), hospitals, health systems, sponsors and contract research organizations (CROs).
  • The partnership of RealTime and Complion bolsters the combined organization's position as a leading provider of eClinical solutions to make clinical research processes more efficient and compliant.
  • "This combination accelerates our mission to deliver leading eRegulatory and additional innovative solutions from RealTime to our customers."
  • About RealTime: RealTime Software Solutions, LLC provides innovative software solutions for clinical research sites, site networks, sponsors and CROs to manage complex clinical research processes with powerful, user-friendly interfaces that are revolutionizing how research gets done.

Radiation Toxicity -- Considerations for Implementing Radiation Dose Limits in Radiopharmaceutical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, October 31, 2022
Bachelor of Science, Army Medical Department (United States), RN, Clinical trial, ARNP, MD, Radiation exposure, Solution, MA, Patient, Radiation, Toxicity, FNP, Industry, MBA, MS, Overalls, Pulmonary toxicity, Food, Doctor of Philosophy, Clinical trial management system, Data management, Probability, Pharmaceutical industry, Medical imaging, Honours degree, Medpace

TORONTO, Oct. 31, 2022 /PRNewswire-PRWeb/ -- As the radiopharmaceutical research and development landscape continues to advance, so do the complexities and challenges associated with clinical trials. Conducting radiopharmaceutical trials presents a unique set of obstacles, such as the challenge of capturing unique radiation induced toxicities in the context of enrolled patients' overall radiation exposure. This requires an understanding of enrolled patients' cumulative radiation exposure from previous radiation treatments and current studies. For clinical radiopharmaceutical studies, the broader team must understand the background of radiation dosimetry, radiation toxicity, normal organ dose constraints and how to capture these metrics within clinical trial data management.

Key Points: 
  • Conducting radiopharmaceutical trials presents a unique set of obstacles, such as the challenge of capturing unique radiation induced toxicities in the context of enrolled patients' overall radiation exposure.
  • This requires an understanding of enrolled patients' cumulative radiation exposure from previous radiation treatments and current studies.
  • For clinical radiopharmaceutical studies, the broader team must understand the background of radiation dosimetry, radiation toxicity, normal organ dose constraints and how to capture these metrics within clinical trial data management.
  • For more information, or to register for this event, visit Radiation Toxicity Considerations for Implementing Radiation Dose Limits in Radiopharmaceutical Trials .

Aspen Insights and RealTime-CTMS Announce Partnership to Streamline Clinical Research Recruitment Workflows

Retrieved on: 
Thursday, October 6, 2022
Storm, Time, Element, Cros, Workflow, Population, LLC, Organization, Emergency, Research, ICD10, Clinical trial management system, CTMS, Technology, Software, Goal, AI, CEO, Marvell Software Solutions Israel, EMR, Clinical trial, Aspen, Forge, Roger Hawkins (drummer), Pharmaceutical industry, Health insurance, Silviculture

This powerful integration includes:

Key Points: 
  • This powerful integration includes:
    Candidate identification by searching patient medical records and clinical data that exceeds standard EMR search capabilities (i.e.
  • Pre-qualified and physician-confirmed delivery of study candidates into RealTime-CTMS to manage the recruitment and enrollment processes and track the patient's research journey.
  • "We are excited to bring our highly effective and proven EMR/EHR database mining technology to clinical research investigative sites to help solve one of the greatest challenges that the clinical research industry is faced with, effective and timely study recruitment," said Aspen Insights' CEO Walter Storm.
  • RealTime Software Solutions, LLC provides innovative software products for clinical trial research sites, site networks, sponsors and CROs to manage complex clinical research processes with powerful, user-friendly interfaces that are revolutionizing how research gets done.

Achieving Successful Cell Therapy Outcomes through Integrated Expertise, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, September 29, 2022
Probability, MSN, MD, Clinical trial management system, Mistake, Industry, Army Medical Department (United States), Clinical trial, Doctor of Philosophy, Food, Research, APRN, Pharmaceutical industry, Medicine, Medpace

TORONTO, Sept. 29, 2022 /PRNewswire-PRWeb/ -- As the cell therapy research and development landscape continues to advance, so do the complexities and challenges associated with clinical trials. Conducting cellular therapy trials presents a unique set of challenges, especially in early phase development. Successful preclinical to clinical transition requires careful planning with the aim of avoiding mistakes and surmounting barriers common to the development and operation of cell therapy trials.

Key Points: 
  • Attendees will learn from an investigational analysis of complex cell therapy studies.
  • TORONTO, Sept. 29, 2022 /PRNewswire-PRWeb/ -- As the cell therapy research and development landscape continues to advance, so do the complexities and challenges associated with clinical trials.
  • Successful preclinical to clinical transition requires careful planning with the aim of avoiding mistakes and surmounting barriers common to the development and operation of cell therapy trials.
  • For more information, or to register for this event, visit Achieving Successful Cell Therapy Outcomes through Integrated Expertise .